Contributions of Insulin-Resistance and Insulin-Secretory Defects to the Pathogenesis of Type 2 Diabetes Mellitus
- Insulin Secretion: Movement at All Levels. Henquin, Jean-Claude; Boitard, Christian; Efendic, Suad; Ferrannini, Ele; Steiner, Donald F.; Cerasi, Erol // Diabetes;Feb2002 Supplement, Vol. 51, pS1
Editorial. Examines the effects of insulin resistance on type two diabetes. Increase of cytosolic beta-cells; Decrease of hyperglycemia; Release of the glucose metabolism.
- Accurate Assessment of Î²-Cells Function. Bergman, Richard N.; Ader, Marilyn; Huecking, Katrin; Van Citters, Gregg // Diabetes;Feb2002 Supplement, Vol. 51, pS212
Only in the last decade did modeling studies predict, and knockout experiments confirm, that type 2 diabetes is a â€œ2-hitâ€ disease in which insulin resistance is necessarily accompanied by Î²-cell defect(s) preventing the compensatory upregulation of insulin secretion. This...
- A Model to Explore the Interaction Between Muscle Insulin Resistance and beta-Cell Dysfunction... Mauvais-Jarvis, Franck; Virkamaki, Antti; Michael, M. Dodson; Winnay, Jonathon N.; Zisman, Ariel; Kulkarni, Rohit N.; Kahn, C. Ronald // Diabetes;Dec2000, Vol. 49 Issue 12, p2126
Explores the interaction between muscle insulin resistance and beta-cell dysfunction in type 2 diabetes. Comparison between glucose tolerance of the two groups of mice; Effects of insulin resistance on beta-cell insulin secretion; Involvement of muscles on insulin regulation.
- Hitting glycaemic targets: tacking insulin resistance and ï¿½-cell failure in Type 2 daibetes. Jamieson, Andrew // Pulse;9/27/2004 Supplement, Vol. 64, p3
Focuses on the insulin resistance and ï¿½-cell failure in type 2 diabetes. Impact of type 2 diabetes on patients; Prevention of microvascular complications; Aim for glycaemic targets. INSET: Executive Summary.
- Angiotensin II in Type 2 Diabetes Mellitus. Kwan Yi Chu; Po Sing Leung // Current Protein & Peptide Science;Feb2009, Vol. 10 Issue 1, p75
Angiotensin II (Ang II) is well-known as a systemic vasoconstrictor but recently a novel role for the peptide in endocrine function has been suggested and it has been linked to the pathophysiology of type 2 diabetes mellitus. According to several large-scale clinical studies, blocking Ang II...
- Is Intestinal Gluconeogenesis a Key Factor in the Early Changes in Glucose Homeostasis Following Gastric Bypass? Hayes, Mark Thomas; Foo, Jonathan; Besic, Vinko; Tychinskaya, Yulia; Stubbs, Richard Strawson // Obesity Surgery;Jun2011, Vol. 21 Issue 6, p759
Background: In 2008, Troy et al. hypothesised that under fasting conditions, intestinal gluconeogenesis generates glucose levels in the portal vein which trigger the portal sensor to change insulin resistance and that this mechanism contributes to the effects of Roux-en-Y gastric bypass (RYGB)...
- Components of Metabolic Syndrome Predicting Diabetes: No Role of Inflammation or Dyslipidemia. Norberg, Margareta; Stenlund, Hans; Lindahl, Bernt; Andersson, Christer; Weinehall, Lars; Hallmans, Garan; Eriksson, Jan W. // Obesity (19307381);Jul2007, Vol. 15 Issue 7, p1875
The article discusses the results of a study on the structure of metabolic syndrome (MetSy) and its components for prediction of type 2 diabetes. It states that inflammation and dyslipidemia factors were not independently related with the risk of diabetes. It says that the core perturbations...
- Use of Homeostatic Model Assessment in Managing Type 2 Diabetes. Kadić, Damira; Dautbegović-Stevanović, Davorka // Folia Medica Facultatis Medicinae Universitatis Saraeviensis;2011, Vol. 46 Issue 1, p48
The prevalence of type 2 diabetes has reached epidemic proportions worldwide, and the incidence of the life-threatening complications of diabetes is increasing. It is of great importance to make a good assessment of newly diagnosed diabetics and to select an appropriate treatment. Without the...
- Stemming the Tide of Type 2 Diabetes: Bring on the “Big Guns”. Buchanan, Thomas A. // Obesity (19307381);Jun2010, Vol. 18 Issue 6, p1065
The author proposes a solution on how to reduce the risk of type 2 diabetes in high-risk individuals in developing and developed countries. He references findings from clinical trials conducted since 2000. He elaborates the lessons that can be learned from the types of interventions studied,...